Ciliatech has raised €3.5m ($3.9m) in Series A funding to develop its glaucoma implant for CE mark approval. Existing investors BNP Développement, Kreaxi and Bernard Chauvin joined the round which bring Cilatech’s total funding to date to €6m.
The Chavanod, France-based company’s glaucoma implant is a cilio-scleral inter-positioning device used to lower intraocular pressure and prevent loss of vision. According to the Ciliatech, it is the first implant that does not require implanting through the anterior chamber of the eye unlike traditional techniques. By keeping this part of the eye chamber intact, complications such as blisters on the eye’s surface and endothelial loss can be avoided.
The implant has demonstrated positive clinical results in which it stabilised intraocular pressure and reduced the need for glaucoma medication. There was no treatment failure and 86% of patients remained medication free after 24 months. Ciliatech said they intend to commence a new trial in Q2 2023 to gather further safety and performance information.
Glaucoma is a leading cause of blindness and there is currently no cure for the condition. Surgery and medication can, however, stall the loss of vision by reducing intraocular pressure. If untreated, the optic nerve becomes damaged which leads to blindness.
“The clinical observations of patients using our first-generation CID after 24 months have been very encouraging. Clinical outcomes on our second-generation device are looking even more promising. We are especially satisfied by the safety profile and the high number of patients still medication-free at 24 months,” said Ciliatech CEO Olivier Benoit.
“We look forward to engaging further with ophthalmic surgeons and glaucoma practitioners, as we progress towards CE mark approval.”